Advances in our understanding of mechanisms of venous thrombus resolution

Expert Review of Hematology

Volumn 9, Issue 1, 2016, Pages 69-78

  Altmann, Johanna ^a   Sharma, Smriti ^a   Lang, Irene M ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angiogenesis; Fibrosis; Inflammation; Thrombosis; Thrombus resolution

Indexed keywords

CD31 ANTIGEN; PHOSPHOLIPID;

ANGIOGENESIS; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SPLENECTOMY; VASCULARIZATION; VEIN THROMBOSIS;

HUMANS; VENOUS THROMBOSIS;

EID: 84948749587     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2016.1112264     Document Type: Review

References (74)

1. ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014;12(10):1580-1590.
2. Singh I, Burnand KG, Collins M, et al. Failure of thrombus to resolve in urokinase-type plasminogen activator geneknockout mice: rescue by normal bone marrow-derived cells. Circulation. 2003;107(6):869-875.
3. Modarai B, Burnand KG, Humphries J, et al. The role of neovascularisation in the resolution of venous thrombus. Thromb Haemost. 2005;93(5):801-809.
4. Henke PK, Wakefield T. Thrombus resolution and vein wall injury: dependence on chemokines and leukocytes. Thromb Res. 2009;123(Suppl 4):S72-78. ∗ Summarizes the role of inflammation in thrombus resolution
5. Frey MK, Alias S, Winter MP, et al. Splenectomy is modifying the vascular remodeling of thrombosis. J Am Heart Assoc. 2014;3(1):e000772. ∗∗ Splenectomy delays thrombus resolution, mediated by increased levels of circulating phospholipids and disturbed angiogenesis
6. Bonderman D, Jakowitsch J, Redwan B, et al. Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2008;28(4):678-684.
7. Varma MR, Varga AJ, Knipp BS, et al. Neutropenia impairs venous thrombosis resolution in the rat. J Vasc Surg. 2003;38(5):1090-1098.
8. Siefert SA, Chabasse C, Mukhopadhyay S, et al. Enhanced venous thrombus resolution in plasminogen activator inhibitor type-2 deficient mice. J Thromb Haemost. 2014;12(10):1706-1716.
9. Nosaka M, Ishida Y, Kimura A, et al. Time-dependent organic changes of intravenous thrombi in stasis-induced deep vein thrombosis model and its application to thrombus age determination. Forensic Sci Int. 2010;195(1-3):143-147.
10. McGuinness CL, Humphries J, Waltham M, et al. Recruitment of labelled monocytes by experimental venous thrombi. Thromb Haemost. 2001;85(6):1018-1024.
11. Humphries J, McGuinness CL, Smith A, et al. Monocyte chemotactic protein-1 (MCP-1) accelerates the organization and resolution of venous thrombi. J Vasc Surg. 1999;30(5):894-899.
12. Henke PK, Wakefield TW, Kadell AM, et al. Interleukin-8 administration enhances venous thrombosis resolution in a rat model. J Surg Res. 2001;99(1):84-91.
13. Von Bruhl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209(4):819-835.
14. Golias C, Tsoutsi E, Matziridis A, et al. Review. Leukocyte and endothelial cell adhesion molecules in inflammation focusing on inflammatory heart disease. In Vivo. 2007;21(5):757-769.
15. Newman PJ, Berndt MC, Gorski J, et al. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science. 1990;247(4947):1219-1222.
16. McMichael AJ, Beverley PCL, Cobbold S, et al., editors. Leucocyte typing III: white cell differentiation antigens. Oxford: Oxford University Press; 1987.
17. Jackson DE, Gully LM, Henshall TL, et al. Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) is associated with a naive B-cell phenotype in human tonsils. Tissue Antigens. 2000;56(2):105-116.
18. Muller WA, Weigl SA, Deng X, et al. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med. 1993;178(2):449-460.
19. Newman DK, Hamilton C, Newman PJ. Inhibition of antigen-receptor signaling by platelet endothelial cell adhesion molecule-1 (CD31) requires functional ITIMs, SHP-2, and p56 (lck). Blood. 2001;97(8):2351-2357.
20. Newton-Nash DK, Newman PJ. A new role for platelet-endothelial cell adhesion molecule-1 (CD31): inhibition of TCR-mediated signal transduction. J Immunol. 1999;163(2):682-688.
21. Rui Y, Liu X, Li N, et al. PECAM-1 ligation negatively regulates TLR4 signaling in macrophages. J Immunol. 2007;179(11):7344-7351.
22. Wilkinson R, Lyons AB, Roberts D, et al. Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) acts as a regulator of B-cell development, B-cell antigen receptor (BCR)-mediated activation, and autoimmune disease. Blood. 2002;100(1):184-193.
23. Cao G, O'Brien CD, Zhou Z, et al. Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration. Am J Physiol Cell Physiol. 2002;282(5):C1181-1190.
24. Kellermair J, Redwan B, Alias S, et al. Platelet endothelial cell adhesion molecule 1 deficiency misguides venous thrombus resolution. Blood. 2013;122(19):3376-3384. ∗∗ Platelet-endothelial CAM 1 mediates monocyte recruitment to resolving thrombi and is essential for thrombus resolution
25. Jones KL, Hughan SC, Dopheide SM, et al. Platelet endothelial cell adhesion molecule-1 is a negative regulator of platelet-collagen interactions. Blood. 2001;98(5):1456-1463.
26. Falati S, Patil S, Gross PL, et al. Platelet PECAM-1 inhibits thrombus formation in vivo. Blood. 2006;107(2):535-541.
27. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003;161(6):1163-1177.
28. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146(6):873-887. ∗ Gives an overview of the cellular and molecular mechanisms of angiogenesis
29. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8(6):464-478.
30. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676.
31. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87(8):3336-3343.
32. Shen H, Clauss M, Ryan J, et al. Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood. 1993;81(10):2767-2773.
33. Blanco R, Gerhardt H. VEGF and Notch in tip and stalk cell selection. Cold Spring Harb Perspect Med. 2013;3(1):a006569.
34. Karsan A. The role of notch in modeling and maintaining the vasculature. Can J Physiol Pharmacol. 2005;83(1):14-23.
35. Louvi A, Artavanis-Tsakonas S. Notch signalling in vertebrate neural development. Nat Rev Neurosci. 2006;7(2):93-102.
36. Phng LK, Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell. 2009;16(2):196-208.
37. Jakobsson L, Franco CA, Bentley K, et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol. 2010;12(10):943-953.
38. Eilken HM, Adams RH. Dynamics of endothelial cell behavior in sprouting angiogenesis. Curr Opin Cell Biol. 2010;22(5):617-625.
39. Eklund L, Olsen BR. Tie receptors and their angiopoietin ligands are contextdependent regulators of vascular remodeling. Exp Cell Res. 2006;312(5):630-641.
40. Thurston G. Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res. 2003;314(1):61-68.
41. Waltham M, Burnand KG, Collins M, et al. Vascular endothelial growth factor enhances venous thrombus recanalisation and organisation. Thromb Haemost. 2003;89(1):169-176.
42. Waltham M, Burnand K, Fenske C, et al. Vascular endothelial growth factor naked DNA gene transfer enhances thrombus recanalization and resolution. J Vasc Surg. 2005;42(6):1183-1189.
43. Modarai B, Humphries J, Burnand KG, et al. Adenovirus-mediated VEGF gene therapy enhances venous thrombus recanalization and resolution. Arterioscler Thromb Vasc Biol. 2008;28(10):1753-1759.
44. Evans CE, Grover SP, Humphries J, et al. Antiangiogenic therapy inhibits venous thrombus resolution. Arterioscler Thromb Vasc Biol. 2014;34(3):565-570.
45. Evans CE, Grover SP, Saha P, et al. Suppression of angiogenic response in local vein wall is associated with reduced thrombus resolution. Thromb Res. 2014;134(3):682-685.
46. Varma MR, Moaveni DM, Dewyer NA, et al. Deep vein thrombosis resolution is not accelerated with increased neovascularization. J Vasc Surg. 2004;40(3):536-542.
47. Alias S, Redwan B, Panzenbock A, et al. Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2014;34(4):810-819. ∗∗ Endothelial cell-specific deletion of the VEGF receptor 2causes misguided thrombus resolution. Defective thrombus angiogenesis may contribute to the pathogenesis of chronic thromboembolic pulmonary hypertension
48. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun. 1992;187(3):1579-1586.
49. Quinn TP, Peters KG, De Vries C, et al. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci U S A. 1993;90(16):7533-7537.
50. Stamou KM, Toutouzas KG, Kekis PB, et al. Prospective study of the incidence and risk factors of postsplenectomy thrombosis of the portal, mesenteric, and splenic veins. Arch Surg. 2006;141(7):663-669.
51. Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33(2):325-331.
52. Wardemann H, Boehm T, Dear N, et al. B-1a B cells that link the innate and adaptive immune responses are lacking in the absence of the spleen. J Exp Med. 2002;195(6):771-780.
53. Kuypers FA. Phospholipid asymmetry in health and disease. Curr Opin Hematol. 1998;5(2):122-131.
54. Sunderkotter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukoc Biol. 1994;55(3):410-422.
55. Ali T, Humphries J, Burnand K, et al. Monocyte recruitment in venous thrombus resolution. J Vasc Surg. 2006;43(3):601-608.
56. Knighton DR, Fiegel VD. Macrophagederived growth factors in wound healing: regulation of growth factor production by the oxygen microenvironment. Am Rev Respir Dis. 1989;140(4):1108-1111.
57. Inkinen K, Turakainen H, Wolff H, et al. Expression and activity of matrix metalloproteinase-2 and -9 in experimental granulation tissue. Apmis. 2000;108(5):318-328.
58. Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3(5):349-363.
59. Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol. 2011;179(3):1074-1080. ∗ Describes the process of endothelialmesenchymal transition and its role in fibrotic disorders
60. Phan SH. The myofibroblast in pulmonary fibrosis. Chest. 2002;122(6 Suppl):286S-289S.
61. Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007;13(8):952-961.
62. Mori L, Bellini A, Stacey MA, et al. Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp Cell Res. 2005;304(1):81-90.
63. Maruoka M, Sakao S, Kantake M, et al. Characterization of myofibroblasts in chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2012;159(2):119-127.
64. Blauwet LA, Edwards WD, Tazelaar HD, et al. Surgical pathology of pulmonary thromboendarterectomy: a study of 54 cases from 1990 to 2001. Hum Pathol. 2003;34(12):1290-1298.
65. Goumans MJ, Liu Z, Ten Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res. 2009;19(1):116-127. ∗ Explains the role of the transforming growth factor (TGF)-β signaling pathway in the vascular system, and the contribution of disturbed TGF-β signaling to several vascular disorders
66. Evans RA, Tian YC, Steadman R, et al. TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. Exp Cell Res. 2003;282(2):90-100.
67. Desmouliere A, Darby IA, Gabbiani G. Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis. Lab Invest. 2003;83(12):1689-1707.
68. Goumans MJ, Van Zonneveld AJ, Ten Dijke P. Transforming growth factor betainduced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis? Trends Cardiovasc Med. 2008;18(8):293-298.
69. Varga J, Jimenez SA. Stimulation of normal human fibroblast collagen production and processing by transforming growth factor-beta. Biochem Biophys Res Commun. 1986;138(2):974-980.
70. Belmadani S, Zerfaoui M, Boulares HA, et al. Microvessel vascular smooth muscle cells contribute to collagen type I deposition through ERK1/2 MAP kinase, alphavbeta3-integrin, and TGF-beta1 in response to ANG II and high glucose. Am J Physiol Heart Circ Physiol. 2008;295(1):H69-76.
71. Durante W, Liao L, Reyna SV, et al. Transforming growth factor-beta (1) stimulates L-arginine transport and metabolism in vascular smooth muscle cells: role in polyamine and collagen synthesis. Circulation. 2001;103(8):1121-1127.
72. Goumans MJ, Valdimarsdottir G, Itoh S, et al. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. Embo J. 2002;21(7):1743-1753.
73. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000;26(1):81-84.
74. Machado RD, Aldred MA, James V, et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat. 2006;27(2):121-132.